Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis

作者全名："Ren, Xiao-Dan; Fu, Xue; He, Yuan-Qun; Li, Chun-Yan; Guo, Meng; Qiao, Min"

作者地址："[Ren, Xiao-Dan; Fu, Xue; He, Yuan-Qun; Li, Chun-Yan; Guo, Meng; Qiao, Min] Chongqing Med Univ, Affiliated Hosp 1, Dept Gastroenterol, Youyi Rd, Chongqing 400016, Peoples R China"

通信作者："Qiao, M (通讯作者)，Chongqing Med Univ, Affiliated Hosp 1, Dept Gastroenterol, Youyi Rd, Chongqing 400016, Peoples R China."

来源：MEDICINE

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:000871577800057

JCR分区：Q2

影响因子：1.6

年份：2022

卷号：101

期号：42

开始页：　

结束页：　

文献类型：Review

关键词：HCV; ribavirin; sofosbuvir-velpatasvir; SVR12

摘要："Introduction: The sofosbuvir-velpatasvir single-tablet regimen (Epclusa) is a newly FDA-approved inhibitor of hepatitis C virus (HCV). This meta-analysis aimed to investigate the safety and efficacy of velpatasvir-sofosbuvir in the treatment of chronic HCV infection. Methods: A comprehensive literature search of PubMed, Cochrane CENTRAL, EMBASE and Web of Science was conducted. Data from eligible studies were pooled in a fixed-effect meta-analysis model, using Open-Meta and RevMan software's. Results: Pooled data showed that velpatasvir-sofosbuvir achieved sustained virological response (SVR12) rates of 94.2% (95% CI 90.7-97.7%, P < .001) in 1277 patients. The addition of ribavirin did not significantly increase the SVR12 (RR = 1.03, 95%CI [0.95, 1.11]) in HCV genotype-1 patients and the SVR12 (RR = 1.09, 95%CI [0.86, 1.38]) in HCV genotype-2 patients. However, adding ribavirin significantly increased SVR12 (RR = 1.13, 95% CI [1.04, 1.23]) in genotype-3 patients. Conclusion: In conclusion, the 12-week regimen of sofosbuvir-velpatasvir was highly effective in HCV patients. Except for genotype-3, adding ribavirin was not associated with significant improvements in SVR12 rates."

基金机构：　

基金资助正文：